Remember meForgot password?
    Log in with Twitter
Press Release

Monoclonal Antibody Therapeutics Market to Record Immense Growth, Revenue to Surge to US $218.97 Billion by 2023

Monoclonal Antibody Therapeutics Market by Application (Cancer, Autoimmune Diseases, Infection, Hematological Diseases, and Others), By Source and By End Users: Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 - 2023

This press release was orginally distributed by SBWire

Sarasota, FL -- (SBWIRE) -- 11/21/2018 -- Global monoclonal antibody therapeutics market is displaying a highly competitive business landscape, finds a new research report by Zion Market Research (ZMR). F. Hoffmann-La Roche Limited, Pfizer Incorporation, Bayer AG, GlaxoSmithKline Plc, and Novartis AG are some of the key vendors of monoclonal antibody therapeutics across the world. These players are focusing aggressively on innovation, as well as on including advanced technologies in their existing products. Over the coming years, they are also expected to take up partnerships and mergers and acquisitions as their key strategy for business development, states the monoclonal antibody therapeutics market study.

Citing an instance, in August 2018, a group of scientists published a study titled "Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection" in Cell Journal. Reportedly, the study unleashes that therapeutic antibodies have the ability to halt the proliferating growth of Ebola virus.


Rise In the Cancer Cases Across The Globe To Boost Market Revenue

"Monoclonal antibody therapeutics market is anticipated to get traction over the coming years, owing to its myriad applications in treatment of cancer, autoimmune ailments, hematological disorders, and infections," says the author of this study. Apart from this, rising incidences of cancer along with humungous investments in R&D activities to develop new antibodies witnessed in Europe and U.S. is anticipated to uplift the growth graph of monoclonal antibody therapeutics market over the forthcoming years. In addition to this, speedy approval as well as commercialization of these antibodies is expected to contribute substantially towards monoclonal antibody therapeutics market revenue in the years ahead.

Escalating production of biosimilars, however, is anticipated to hamper the growth of monoclonal antibody therapeutics market in the near future. In addition to this, patent expiry of large number of monoclonal antibodies along with the complex & costly procedure involved in production of these antibodies is forecast to obstruct the monoclonal antibody therapeutics market scope in the coming years.

Wide Acceptance Of Monoclonal Antibodies To Push North American Dominance

Regionally, North America has been leading the worldwide monoclonal antibody therapeutics market and is anticipated to continue on the dominant position in the years to come, states the monoclonal antibody therapeutics market study. Rapid acceptance of monoclonal antibodies in the region is the main factor behind the dominance of the North America monoclonal antibody therapeutics market. The high number of market players being headquartered in North America is another significant factor that is supporting the progression of this regional monoclonal antibody therapeutics market.

Get Free Sample Research Report @

The global monoclonal antibody therapeutics market is segmented as follows:

By Application

Autoimmune Diseases
Hematological Diseases
By Source

By End-User

Private Clinics
Research Institute
By Region

North America
The U.S.
Asia Pacific
Latin America
The Middle East and Africa

For more information on this press release visit:

Media Relations Contact

Steven Schulz
Research Analyst
zion market research
Telephone: 49-322 210 92714
Email: Click to Email Steven Schulz

Latest News
Top News